Panelists discuss how the data from the BRAVE-AA1 and BRAVE-AA2 phase 3 trials demonstrated the safety and efficacy of baricitinib, leading to its FDA approval in 2022 as the first systemic treatment ...

Panelists discuss how switching therapies in patients with alopecia areata (AA) is often necessary when initial treatments ...

WALTHAM, Mass. - Q32 Bio Inc. (NASDAQ: QTTB), a clinical-stage biotechnology firm trading at $3.18 with a market cap of $38.55 million, announced a strategic shift to prioritize the development of its ...

A phase 3 study demonstrated that ritlecitinib was effective and well tolerated in patients with alopecia areata and ≥ 25% ...

Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced a corporate restructuring to ...

samantha busch shows off incredible hair growth after battling alopecia areata, revealing resilience, treatments, and a ...

The risk for alopecia areata is increased among patients with lower serum levels of vitamin D and zinc, but no relationship was observed with copper.

The global alopecia treatment market size was valued at USD 3.48 billion in 2024 and is projected to reach from USD 3.62 billion in 2025 to USD 5.20 billion by 2033, growing at a CAGR of 4.1% during ...

59% van de patiënten met ernstige alopecia areata had 2 jaar na down-titratie van baricitinib 4 mg naar 2 mg nog een respons.

The goal is to find a cure for alopecia areata, an autoimmune disease that causes hair loss in distinct round patches.